Evolus Inc (EOLS)

$9.96 +0.03 (0.30%)
Market Cap 640.25M
Revenue (ttm) 266.27M
Net Income (ttm) -50.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.94%
Debt to Equity Ratio -18.46
Volume 762,050
Avg Vol 1,128,860
Day's Range N/A - N/A
Shares Out 64.48M
Stochastic %K 45%
Beta 1.00
Analysts Strong Sell
Price Target $24.29

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 949 284 4555
Address:
520 Newport Center Drive, Suite 1200, Newport Beach, United States
Mandi63
Mandi63 Jun. 13 at 5:30 PM
$AEON LOOK FOR A STRONG CLOSE…HEADED FOR THE WEEKEND…FDA MEETING…DATA PRESENTED INSIDE BUYING…SHARES BEING LOCKED Up …JOREY CHERNETT BOUGHT 1,250,000 PLUS SHARE… THREE CONFIRMED 5% SHAREHOLDERS….ALREADY APPROVED DRUG BEING SOLD THOUGH INTERNATIONAL PARTNER $EOLS….LOOK FOR FAST-TRACK APPROVAL…
0 · Reply
Mandi63
Mandi63 Jun. 12 at 12:41 PM
$AEON ALREADY APPROVED DRUG…NATIONAL PARTNER $EOLS FDA MEETING COMING WITH DATA RESULTS SHAREHOLDER MEETING TOMORROW….$1.00 PLUS INSIDE BUYING NEW CEO WITH 25 YEARS EXPERIENCE INVOLVED WITH MERGER BUYOUT $10.00 PLUS
1 · Reply
Mandi63
Mandi63 Jun. 11 at 5:06 PM
$AEON Clearpath CEO JOREY Chernett bought. 10% of AEON.. Inside buying with last date 5/21 National Partner $EOLS $5.00-25.00 price target $360.00
0 · Reply
Rossumopossum
Rossumopossum Jun. 11 at 1:46 PM
$EOLS lets see this thing go today. Its overdue imo nfa
1 · Reply
goofyfoot
goofyfoot Jun. 11 at 10:58 AM
$EOLS Evolysse™ Recognized in 2025 Shape Skin Awards Business Wire NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (EOLS.NaE) , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards: * Evolysse™ Recognized as the Best Filler for 2025 with its recently launched injectable hyaluronic acid gel line * Best Membership Treatment Model for Club Evolus™, its proprietary consumer rewards program The annual Shape Skin Awards highlight innovation and performance across the skincare and aesthetics industry. This year the judging panel of board-certified dermatologists and specialists evaluated more than 800 products and treatments, ultimately selecting winners across a range of categories.
0 · Reply
ladygotbags
ladygotbags Jun. 10 at 9:13 PM
$EOLS Insider purchase!
1 · Reply
goofyfoot
goofyfoot Jun. 9 at 5:34 PM
$EOLS C'mon! Why is this dropping?
3 · Reply
DCRMIA
DCRMIA Jun. 7 at 3:45 PM
$EOLS Extremely bullish!🚀📈
0 · Reply
DCRMIA
DCRMIA Jun. 6 at 3:14 PM
I anticipate significant growth in $EOLS this month. I am quite prepared🚀🚀🚀
0 · Reply
valueforme
valueforme Jun. 6 at 2:50 PM
$EOLS Finally reentered here with a mid-sized position. Love this "drop the F word campaign"
0 · Reply
Latest News on EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 13, 2025, 4:05 PM EDT - 3 days ago

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolysse™ Recognized in 2025 Shape Skin Awards

Jun 10, 2025, 8:00 AM EDT - 6 days ago

Evolysse™ Recognized in 2025 Shape Skin Awards

Evolus Announces Departure of its Chief Financial Officer

May 27, 2025, 4:15 PM EDT - 20 days ago

Evolus Announces Departure of its Chief Financial Officer

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 22, 2025, 8:00 AM EDT - 25 days ago

Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:13 PM EDT - 5 weeks ago

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

Evolus Reports First Quarter 2025 Results

May 7, 2025, 4:05 PM EDT - 5 weeks ago

Evolus Reports First Quarter 2025 Results

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

May 5, 2025, 4:05 PM EDT - 6 weeks ago

Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 7 weeks ago

Evolus to Report First Quarter Financial Results on May 7, 2025

Evolus Announces Commercial Launch of Evolysse™

Apr 16, 2025, 8:00 AM EDT - 2 months ago

Evolus Announces Commercial Launch of Evolysse™

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Apr 15, 2025, 8:00 AM EDT - 2 months ago

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 2 months ago

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:18 PM EST - 3 months ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Evolus posts quarterly profit on strong sales of cosmetic injection

Mar 4, 2025, 4:17 PM EST - 3 months ago

Evolus posts quarterly profit on strong sales of cosmetic injection

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Mar 4, 2025, 4:05 PM EST - 3 months ago

Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Feb 27, 2025, 8:00 AM EST - 3 months ago

Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Feb 20, 2025, 8:00 AM EST - 4 months ago

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Feb 18, 2025, 8:00 AM EST - 4 months ago

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:45 PM EST - 4 months ago

US FDA approves Evolus' anti-wrinkle gels

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Feb 13, 2025, 1:30 PM EST - 4 months ago

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Jan 21, 2025, 8:00 AM EST - 5 months ago

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Jan 14, 2025, 2:00 PM EST - 5 months ago

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 7:28 PM EST - 7 months ago

Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript

Evolus Reports Third Quarter 2024 Results

Nov 6, 2024, 4:05 PM EST - 7 months ago

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Nov 1, 2024, 8:00 AM EDT - 8 months ago

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Oct 31, 2024, 2:02 PM EDT - 8 months ago

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Oct 29, 2024, 8:00 AM EDT - 8 months ago

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

Evolus to Report Third Quarter Financial Results on November 6, 2024

Oct 23, 2024, 8:00 AM EDT - 8 months ago

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Sep 6, 2024, 8:00 AM EDT - 10 months ago

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 10:22 PM EDT - 11 months ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Jul 31, 2024, 4:09 PM EDT - 11 months ago

Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Jul 31, 2024, 4:05 PM EDT - 11 months ago

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

Evolus to Hold Investor Day on September 12, 2024

Jul 31, 2024, 8:00 AM EDT - 11 months ago

Evolus to Hold Investor Day on September 12, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Jul 30, 2024, 8:00 AM EDT - 11 months ago

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 25, 2024, 8:00 AM EDT - 11 months ago

Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference

Evolus to Report Second Quarter Financial Results on July 31, 2024

Jul 17, 2024, 8:00 AM EDT - 11 months ago

Evolus to Report Second Quarter Financial Results on July 31, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

Evolus: Chiseling Away At The Aesthetic Market

May 22, 2024, 7:00 AM EDT - 1 year ago

Evolus: Chiseling Away At The Aesthetic Market

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

May 20, 2024, 8:30 AM EDT - 1 year ago

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit

May 15, 2024, 8:30 AM EDT - 1 year ago

Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO Summit

Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year

May 10, 2024, 9:10 AM EDT - 1 year ago

Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year

Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:27 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q1 2024 Earnings Call Transcript

Evolus Reports First Quarter 2024 Results and Provides Business Update

May 7, 2024, 4:05 PM EDT - 1 year ago

Evolus Reports First Quarter 2024 Results and Provides Business Update

Evolus to Report First Quarter Financial Results on May 7, 2024

Apr 23, 2024, 4:30 PM EDT - 1 year ago

Evolus to Report First Quarter Financial Results on May 7, 2024

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20, 2024, 2:05 PM EDT - 1 year ago

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Evolus, Inc. (EOLS) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 10:40 PM EST - 1 year ago

Evolus, Inc. (EOLS) Q4 2023 Earnings Call Transcript

Mandi63
Mandi63 Jun. 13 at 5:30 PM
$AEON LOOK FOR A STRONG CLOSE…HEADED FOR THE WEEKEND…FDA MEETING…DATA PRESENTED INSIDE BUYING…SHARES BEING LOCKED Up …JOREY CHERNETT BOUGHT 1,250,000 PLUS SHARE… THREE CONFIRMED 5% SHAREHOLDERS….ALREADY APPROVED DRUG BEING SOLD THOUGH INTERNATIONAL PARTNER $EOLS….LOOK FOR FAST-TRACK APPROVAL…
0 · Reply
Mandi63
Mandi63 Jun. 12 at 12:41 PM
$AEON ALREADY APPROVED DRUG…NATIONAL PARTNER $EOLS FDA MEETING COMING WITH DATA RESULTS SHAREHOLDER MEETING TOMORROW….$1.00 PLUS INSIDE BUYING NEW CEO WITH 25 YEARS EXPERIENCE INVOLVED WITH MERGER BUYOUT $10.00 PLUS
1 · Reply
Mandi63
Mandi63 Jun. 11 at 5:06 PM
$AEON Clearpath CEO JOREY Chernett bought. 10% of AEON.. Inside buying with last date 5/21 National Partner $EOLS $5.00-25.00 price target $360.00
0 · Reply
Rossumopossum
Rossumopossum Jun. 11 at 1:46 PM
$EOLS lets see this thing go today. Its overdue imo nfa
1 · Reply
goofyfoot
goofyfoot Jun. 11 at 10:58 AM
$EOLS Evolysse™ Recognized in 2025 Shape Skin Awards Business Wire NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (EOLS.NaE) , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards: * Evolysse™ Recognized as the Best Filler for 2025 with its recently launched injectable hyaluronic acid gel line * Best Membership Treatment Model for Club Evolus™, its proprietary consumer rewards program The annual Shape Skin Awards highlight innovation and performance across the skincare and aesthetics industry. This year the judging panel of board-certified dermatologists and specialists evaluated more than 800 products and treatments, ultimately selecting winners across a range of categories.
0 · Reply
ladygotbags
ladygotbags Jun. 10 at 9:13 PM
$EOLS Insider purchase!
1 · Reply
goofyfoot
goofyfoot Jun. 9 at 5:34 PM
$EOLS C'mon! Why is this dropping?
3 · Reply
DCRMIA
DCRMIA Jun. 7 at 3:45 PM
$EOLS Extremely bullish!🚀📈
0 · Reply
DCRMIA
DCRMIA Jun. 6 at 3:14 PM
I anticipate significant growth in $EOLS this month. I am quite prepared🚀🚀🚀
0 · Reply
valueforme
valueforme Jun. 6 at 2:50 PM
$EOLS Finally reentered here with a mid-sized position. Love this "drop the F word campaign"
0 · Reply
Mandi63
Mandi63 Jun. 6 at 11:38 AM
$AEON YES SOMETHING WILL HAPPEN IN JUNE..CONTINUED RISE OF SHARE PRICE… WE HAVE INSIDE BUYING… 10% PURCHASE SHARES FROM JOREY CHERNETT THE CEO OF CLEARPATH LOW PUBLIC FLOAT OF 7.68 MILLION ALREADY APPROVED DRUG WITH INTERNATIONAL PARTNER $EOLS UPCOMING FDA MEETING WITH RESULT
2 · Reply
Finitemaf
Finitemaf Jun. 4 at 5:48 PM
$EOLS good add sub $10. Hearing great things about the lip filer/injections. We will see north of $15 by years end imho
1 · Reply
Allf2
Allf2 Jun. 2 at 10:07 PM
$EOLS .. double x2
1 · Reply
Mandi63
Mandi63 Jun. 2 at 5:58 PM
$AEON $EOLS $SANA $CDIO $AEON Aeon...INSIDE BUYING TOOO… JUST CHECKED SEC FILINGS…NEW 13D 10% OWNER 1,128.500 SHARES….BAM…
1 · Reply
DRRG
DRRG Jun. 1 at 6:06 AM
$EOLS — Very bullish. Evolysse is shaping up to be much more than just another filler. Early adoption is showing exceptional performance—far beyond initial expectations—across both on-label and off-label applications. What truly differentiates Evolysse is its manufacturing process: it’s the only hyaluronic acid (HA) gel on the market made without heat, actually made using freezing temperatures. This preserves the integrity of the HA chains, resulting in longer, less fragmented molecules that closely mimic the body’s natural HA. The benefits? • Less swelling • Slower degradation • Greater longevity per syringe • Minimal immune response, as the body recognizes it as “self” The science is translating into strong clinical outcomes and patient satisfaction—early indicators that Evolysse could be a category disruptor. The fact they are the only ones that have the “Ozempic face“ indication is $$$ because half our patients are on GLP-1’s. I’m adding here definitely watching this one closely.
2 · Reply
Mandi63
Mandi63 May. 30 at 5:09 PM
$AEON THIS IS A COMPANY BASED IN CALIFORNIA…ALREDY APPROVED PRODUCT SOLD THOUGH THIER INTERNATIONAL PARTNER $EOLS
0 · Reply
Mandi63
Mandi63 May. 29 at 12:49 PM
$AEON $SANA $CDIO $EOLS $AEON HOT READY TO MOVE..7.68 MILLION PUBLIC SHARES AND LARGE SHAREHOLDERS We have had two 30 million volumes days…? big inside buying… time to move up…raise your ask buy the ask… was trading $10-25.00 before 1-72
0 · Reply
Mandi63
Mandi63 May. 28 at 3:21 PM
$AEON GREAT RESULTS COMING ON ALREADY APPROVED DRUG BUY OUT MERGER DEAL WITH INTERNATIONAL PARTNER $EOLS
0 · Reply
Allf2
Allf2 May. 28 at 1:39 PM
$EOLS buy
1 · Reply
JT161803
JT161803 May. 28 at 1:32 PM
$EOLS
0 · Reply
Mandi63
Mandi63 May. 28 at 1:32 PM
$AEON $CDIO $SANA $EOLS $AEON TWO WORDS INSIDE BUYING
0 · Reply
Allf2
Allf2 May. 28 at 11:35 AM
$EOLS Sandra Beaver’s decision to join Lyra Health, which attained unicorn status in 2020, is seen as a strategic career move rather than a reflection of any diminished confidence in Evolus. She has previously collaborated with Lyra’s CEO at Experian (OTC:EXPGF) and is not planning to sell her approximately 167,000 shares in Evolus, signaling her belief in the company’s long-term prospects.
0 · Reply